• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝硬化肝脏的磁共振成像：肝细胞癌的诊断及治疗反应评估 - 第2部分

Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 2.

作者信息

Ramalho Miguel, Matos António P, AlObaidy Mamdoh, Velloni Fernanda, Altun Ersan, Semelka Richard C

机构信息

Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, and Hospital Garcia de Orta, Almada, Portugal.

Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, and King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

出版信息

Radiol Bras. 2017 Mar-Apr;50(2):115-125. doi: 10.1590/0100-3984.2015.0140.

DOI:10.1590/0100-3984.2015.0140
PMID:28428655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5397003/
Abstract

In the second part of this review, we will describe the ancillary imaging features of hepatocellular carcinoma (HCC) that can be seen on standard magnetic resonance imaging (MRI) protocol, and on novel and emerging protocols such as diffusion weighted imaging and utilization of hepatocyte-specific/hepatobiliary contrast agent. We will also describe the morphologic sub-types of HCC, and give a simplified non-invasive diagnostic algorithm for HCC, followed by a brief description of the liver imaging reporting and data system (LI-RADS), and MRI assessment of tumor response following locoregional therapy.

摘要

在本综述的第二部分，我们将描述肝细胞癌（HCC）的辅助成像特征，这些特征可在标准磁共振成像（MRI）协议以及诸如扩散加权成像和使用肝细胞特异性/肝胆造影剂等新型和新兴协议中看到。我们还将描述HCC的形态学亚型，并给出一种简化的HCC非侵入性诊断算法，随后简要介绍肝脏成像报告和数据系统（LI-RADS）以及局部区域治疗后肿瘤反应的MRI评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/7d918f34afbd/rb-50-02-0115-g12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/37017bcefa3e/rb-50-02-0115-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/89515897c475/rb-50-02-0115-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/96957a6d7cd1/rb-50-02-0115-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/d4006500c862/rb-50-02-0115-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/1105b3034021/rb-50-02-0115-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/d0254f05f861/rb-50-02-0115-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/02d1af0a771a/rb-50-02-0115-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/cdc74ed3ade6/rb-50-02-0115-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/e035d569967c/rb-50-02-0115-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/6a6c56c41f4f/rb-50-02-0115-g10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/bea643b83038/rb-50-02-0115-g11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/7d918f34afbd/rb-50-02-0115-g12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/37017bcefa3e/rb-50-02-0115-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/89515897c475/rb-50-02-0115-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/96957a6d7cd1/rb-50-02-0115-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/d4006500c862/rb-50-02-0115-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/1105b3034021/rb-50-02-0115-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/d0254f05f861/rb-50-02-0115-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/02d1af0a771a/rb-50-02-0115-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/cdc74ed3ade6/rb-50-02-0115-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/e035d569967c/rb-50-02-0115-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/6a6c56c41f4f/rb-50-02-0115-g10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/bea643b83038/rb-50-02-0115-g11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1720/5397003/7d918f34afbd/rb-50-02-0115-g12.jpg

相似文献

1
Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 2.肝硬化肝脏的磁共振成像：肝细胞癌的诊断及治疗反应评估 - 第2部分
Radiol Bras. 2017 Mar-Apr;50(2):115-125. doi: 10.1590/0100-3984.2015.0140.
2
Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?肝细胞癌：钆塞酸增强磁共振和弥散加权成像的 LI-RADS v2017 能否提高诊断准确性？
World J Gastroenterol. 2019 Feb 7;25(5):622-631. doi: 10.3748/wjg.v25.i5.622.
3
Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1.肝硬化肝脏的磁共振成像：肝细胞癌的诊断及治疗反应评估 - 第1部分
Radiol Bras. 2017 Jan-Feb;50(1):38-47. doi: 10.1590/0100-3984.2015.0132.
4
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.在一项多中心回顾性研究中，1006 个结节的对比超声 LI-RADS LR-5 可识别肝硬化中的肝细胞癌。
J Hepatol. 2018 Mar;68(3):485-492. doi: 10.1016/j.jhep.2017.11.007. Epub 2017 Nov 11.
5
Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.比较 AASLD 和 LI-RADS 标准在诊断小于 3cm 的 HCC 方面的准确性。
J Hepatol. 2018 Apr;68(4):715-723. doi: 10.1016/j.jhep.2017.12.014. Epub 2017 Dec 21.
6
Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases.双表型原发性肝癌（肝内胆管癌）的影像学特征及模仿肝细胞癌的可能性：61例CT和MRI特征的LI-RADS分析
AJR Am J Roentgenol. 2016 Jul;207(1):25-31. doi: 10.2214/AJR.15.14997. Epub 2016 Feb 11.
7
Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.高危人群肝细胞癌无创诊断标准化算法的观察者间和模态间一致性：CEUS-LI-RADS 与 MRI-LI-RADS。
Eur Radiol. 2018 Oct;28(10):4254-4264. doi: 10.1007/s00330-018-5379-1. Epub 2018 Apr 19.
8
LI-RADS 2017: An update.LI-RADS 2017：更新。
J Magn Reson Imaging. 2018 Jun;47(6):1459-1474. doi: 10.1002/jmri.26027. Epub 2018 Apr 6.
9
Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).诊断 CT/MRI 肝脏影像报告和数据系统（LI-RADS）中的陷阱和问题。
Eur Radiol. 2019 Mar;29(3):1124-1132. doi: 10.1007/s00330-018-5641-6. Epub 2018 Aug 16.
10
Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update.肝脏影像报告和数据系统（LI-RADS）评估肝细胞癌的主要及辅助磁共振特征：综述与更新
Infect Agent Cancer. 2017 Apr 28;12:23. doi: 10.1186/s13027-017-0132-y. eCollection 2017.

引用本文的文献

1
Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.评估肝细胞癌的局部区域治疗反应：肝胆对比剂与细胞外对比剂的比较。
Abdom Radiol (NY). 2021 Aug;46(8):3565-3578. doi: 10.1007/s00261-021-03076-x. Epub 2021 Apr 15.
2
Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis.循环游离DNA联合磁共振成像用于肝硬化患者肝细胞癌的早期检测
Cancers (Basel). 2021 Jan 29;13(3):521. doi: 10.3390/cancers13030521.
3
Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma.

本文引用的文献

1
Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma.钆塞酸二钠增强肝细胞期图像对LI-RADS系统诊断肝细胞癌的附加价值
Magn Reson Med Sci. 2016;15(1):49-59. doi: 10.2463/mrms.2014-0149. Epub 2015 Jun 23.
2
Magnetic resonance imaging of the cirrhotic liver: An update.肝硬化肝脏的磁共振成像：最新进展
World J Hepatol. 2015 Mar 27;7(3):468-87. doi: 10.4254/wjh.v7.i3.468.
3
The role of gadoxetic acid as a paramagnetic contrast medium in the characterization and detection of focal liver lesions: a review.
钆塞酸二钠增强磁共振成像在肝细胞癌中的应用。
World J Surg Oncol. 2020 Aug 22;18(1):219. doi: 10.1186/s12957-020-01996-4.
4
Diffusion-weighted imaging and apparent diffusion coefficient values for evaluating terminal ileitis in patients with Crohn's disease.用于评估克罗恩病患者终末回肠炎的扩散加权成像及表观扩散系数值
Radiol Bras. 2019 Nov-Dec;52(6):361-367. doi: 10.1590/0100-3984.2019.0011.
5
Microvascular invasion in hepatocellular carcinoma: is it predictable with quantitative computed tomography parameters?肝细胞癌中的微血管侵犯：能否通过定量计算机断层扫描参数预测？
Radiol Bras. 2019 Sep-Oct;52(5):287-292. doi: 10.1590/0100-3984.2018.0123.
6
CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners.《CT-MRI肝脏影像报告和数据系统（LI-RADS）2017版：初学者综合指南》
J Clin Transl Hepatol. 2018 Jun 28;6(2):222-236. doi: 10.14218/JCTH.2017.00062. Epub 2018 Feb 22.
7
Fat-containing liver lesions: a pictorial review.含脂肪的肝脏病变：图文综述
Radiol Bras. 2018 Jan-Feb;51(1):52-57. doi: 10.1590/0100-3984.2016.0147.
8
Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.磁共振成像在胃肠病学实践中的贡献：用于胃肠病学的 MRI。
Dig Dis Sci. 2018 May;63(5):1102-1122. doi: 10.1007/s10620-018-4991-x.
9
Computed tomography angiography study of variations of the celiac trunk and hepatic artery in 100 patients.100例患者腹腔干和肝动脉变异的计算机断层血管造影研究
Radiol Bras. 2018 Jan-Feb;51(1):32-36. doi: 10.1590/0100-3984.2016.0179.
钆塞酸作为一种顺磁性对比剂在肝脏局灶性病变的特征描述和检测中的作用：综述
Radiol Bras. 2015 Jan-Feb;48(1):43-51. doi: 10.1590/0100-3984.2013.1794.
4
Hepatobiliary contrast agents: differential diagnosis of focal hepatic lesions, pitfalls and other indications.肝胆造影剂：肝脏局灶性病变的鉴别诊断、陷阱及其他适应证
Radiol Bras. 2014 Sep-Oct;47(5):301-9. doi: 10.1590/0100-3984.2013.1867.
5
Hepatocellular carcinoma: diagnostic criteria by imaging techniques.肝细胞癌：影像学技术诊断标准
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):795-812. doi: 10.1016/j.bpg.2014.08.005. Epub 2014 Aug 23.
6
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.肝细胞癌的CT与MR成像诊断及分期：第二部分。细胞外对比剂、肝胆对比剂及辅助成像特征。
Radiology. 2014 Oct;273(1):30-50. doi: 10.1148/radiol.14132362.
7
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.LI-RADS（肝脏成像报告和数据系统）：LI-RADS 管理工作组的总结、讨论和共识，以及未来方向。
Hepatology. 2015 Mar;61(3):1056-65. doi: 10.1002/hep.27304. Epub 2014 Dec 12.
8
LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas.LI-RADS 分类在肝细胞癌风险患者中的良性和可能良性发现：图像图谱。
AJR Am J Roentgenol. 2014 Jul;203(1):W48-69. doi: 10.2214/AJR.13.12169.
9
Consensus report from the 6th International forum for liver MRI using gadoxetic acid.第六次钆塞酸二钠肝脏MRI国际论坛共识报告
J Magn Reson Imaging. 2014 Sep;40(3):516-29. doi: 10.1002/jmri.24419. Epub 2013 Nov 8.
10
Hepatocellular carcinoma and other hepatic malignancies: MR imaging.肝细胞癌及其他肝脏恶性肿瘤：磁共振成像
Radiol Clin North Am. 2014 Jul;52(4):683-707. doi: 10.1016/j.rcl.2014.02.015. Epub 2014 Apr 13.